JP2023526590A - ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物 - Google Patents

ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物 Download PDF

Info

Publication number
JP2023526590A
JP2023526590A JP2022569031A JP2022569031A JP2023526590A JP 2023526590 A JP2023526590 A JP 2023526590A JP 2022569031 A JP2022569031 A JP 2022569031A JP 2022569031 A JP2022569031 A JP 2022569031A JP 2023526590 A JP2023526590 A JP 2023526590A
Authority
JP
Japan
Prior art keywords
subject
certain embodiments
mtor inhibitor
ligand trap
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569031A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021231851A5 (https=
JP2023526590A5 (https=
Inventor
アカル，メリフ
シュヴィカート，マルティン
ジュペリ，マデュリカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2023526590A publication Critical patent/JP2023526590A/ja
Publication of JPWO2021231851A5 publication Critical patent/JPWO2021231851A5/ja
Publication of JP2023526590A5 publication Critical patent/JP2023526590A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022569031A 2020-05-15 2021-05-14 ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物 Pending JP2023526590A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025955P 2020-05-15 2020-05-15
US63/025,955 2020-05-15
PCT/US2021/032434 WO2021231851A1 (en) 2020-05-15 2021-05-14 Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors

Publications (3)

Publication Number Publication Date
JP2023526590A true JP2023526590A (ja) 2023-06-22
JPWO2021231851A5 JPWO2021231851A5 (https=) 2024-05-22
JP2023526590A5 JP2023526590A5 (https=) 2024-05-22

Family

ID=78525025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569031A Pending JP2023526590A (ja) 2020-05-15 2021-05-14 ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物

Country Status (11)

Country Link
US (1) US20230210827A1 (https=)
EP (2) EP4149441A4 (https=)
JP (1) JP2023526590A (https=)
KR (1) KR20230010641A (https=)
CN (1) CN115551487A (https=)
AU (1) AU2021273065A1 (https=)
BR (1) BR112022022830A2 (https=)
CA (1) CA3177632A1 (https=)
IL (1) IL298156A (https=)
MX (1) MX2022014080A (https=)
WO (1) WO2021231851A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018185341A1 (en) * 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
WO2018231905A1 (en) * 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
JP2019522022A (ja) * 2016-07-27 2019-08-08 アクセルロン ファーマ， インコーポレイテッド 骨髄線維症を処置するための方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
CN104968801B (zh) 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
IL258574B2 (en) * 2015-11-11 2025-01-01 Novartis Ag Uses of myostatin antagonists, combinations containing them and their uses
US20220372136A1 (en) * 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019522022A (ja) * 2016-07-27 2019-08-08 アクセルロン ファーマ， インコーポレイテッド 骨髄線維症を処置するための方法および組成物
WO2018185341A1 (en) * 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
WO2018231905A1 (en) * 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 136 (Supplement 1), JPN6025027372, November 2020 (2020-11-01), pages 17, ISSN: 0005770320 *
CURRENT DRUG TARGETS, vol. 20(16), JPN6025027374, 2019, pages 1603 - 1623, ISSN: 0005770321 *
PEDIATRIC HEMATOLOGY ONCOLOGY JOURNAL, vol. 2(4), JPN6025027373, 2017, pages 121 - 126, ISSN: 0005770319 *

Also Published As

Publication number Publication date
KR20230010641A (ko) 2023-01-19
US20230210827A1 (en) 2023-07-06
EP4149441A1 (en) 2023-03-22
BR112022022830A2 (pt) 2022-12-13
AU2021273065A1 (en) 2022-12-15
WO2021231851A1 (en) 2021-11-18
MX2022014080A (es) 2022-12-07
EP4149441A4 (en) 2024-03-13
IL298156A (en) 2023-01-01
EP4649961A3 (en) 2026-02-25
CA3177632A1 (en) 2021-11-18
EP4649961A2 (en) 2025-11-19
CN115551487A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
JP7315487B2 (ja) 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
JP7146850B2 (ja) 貧血の治療に使用するためのバイオマーカー
JP6796626B2 (ja) 無効赤血球生成を処置するための方法および組成物
TWI472336B (zh) 使用ｇｄｆ阱以增加紅血球水平
JP5909446B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
JP2020183390A (ja) 貧血の治療方法
JP2020097629A (ja) 潰瘍を処置するための方法および組成物
JP2023526590A (ja) ＡｃｔＲＩＩＢリガンドトラップ及びｍＴＯＲ阻害剤を使用して貧血を治療するための方法及び組成物
EA049358B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ АНЕМИИ С ПРИМЕНЕНИЕМ ЛИГАНДОВ-ЛОВУШЕК ActRIIB И ИНГИБИТОРОВ mTOR
AU2015202035B2 (en) Use of GDF traps to increase red blood cell levels
HK40011608A (en) Compositions for treating myelofibrosis
HK40011608B (en) Compositions for treating myelofibrosis
HK40012688A (en) Methods for treating anemia
HK1245147A1 (zh) 激活素-actrii的拮抗劑及在提高紅細胞水平中的用途
HK1234417B (en) Methods for increasing red blood cell levels and treating sickle-cell disease
HK1236427B (en) Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
HK1203413B (en) Compositions for treating iron overload in thalassemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410